Dermata Therapeutics, Inc. (DRMA)
Automate Your Wheel Strategy on DRMA
With Tiblio's Option Bot, you can configure your own wheel strategy including DRMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DRMA
- Rev/Share 0.0
- Book/Share 1.4164
- PB 0.4771
- Debt/Equity 0.0
- CurrentRatio 6.9657
- ROIC -1.7908
- MktCap 4310332.0
- FreeCF/Share -2.0161
- PFCF -0.4148
- PE -0.3041
- Debt/Assets 0.0
- DivYield 0
- ROE -2.7082
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne - - Over 30 million acne patients seek treatment in the U.S. each year - SAN DIEGO , March 26, 2025 /PRNewswire/ -- Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial …
Read More
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis - - The Company also has an issued patent in Japan covering their DMT410 program for the treatment of hyperhidrosis - SAN DIEGO, CA / ACCESS Newswire / February 25, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and …
Read More
About Dermata Therapeutics, Inc. (DRMA)
- IPO Date 2021-08-13
- Website https://www.dermatarx.com
- Industry Biotechnology
- CEO Mr. Gerald T. Proehl
- Employees 8